Quinazolin-4(3H)-ones capable of upregulating the expression of endogenous apolipoprotein A-1

Bibliography

• Rosamond WD, Chambless LE, Folsom AR, Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med 1998;21:861-7
   Google Scholar
• Castelli WP, Garrison RJ, Wilson PW, Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA 1986;256(20):2835-8
   PubMed Web of Science ®Google Scholar
• Sharrett AR, Ballantyne CM, Coady SA, Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001;104(10):1108-13
   PubMed Web of Science ®Google Scholar
• Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease:the Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-9
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland coronary prevention study group. N Engl J Med 1995;333:1301-7
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: cholesterol and recurrent events trial investigators. N Engl J Med 1996;335:1001-9
   PubMed Web of Science ®Google Scholar
• Chapman MJ, Assmann G, Fruchart JC, Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid–a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004;20(8):1253-68
   PubMed Web of Science ®Google Scholar
• Downs JR, Clearfield M, Weis S, Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS (Air Force/Texas coronary atherosclerosis prevention study). J Am Med Assoc 1998;279:1615-22
   PubMed Web of Science ®Google Scholar
• Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 1973;180:1332-9
   PubMed Web of Science ®Google Scholar
• Handattu SP, Garber DW, Horn DC, ApoA-I mimetic peptides with differing ability to inhibit atherosclerosis also exhibit differences in their interactions with membrane bilayers. J Biol Chem 2007;282:1980-8
   PubMed Web of Science ®Google Scholar
• Resverlogix Corp. WO2006045096; 2006
   Google Scholar
• Resverlogix Corp. WO2008092231; 2008
   Google Scholar
• Resverlogix Corp. US20070099826; 2007
   Google Scholar
• Resverlogix Corp. WO2007016525; 2007
   Google Scholar
• Resverlogix Corp. WO2009158404; 2009
   Google Scholar
• Resverlogix Corp. WO2010079431; 2010
   Google Scholar
• Mhaske SB, Argade P. The chemistry of recently isolated naturally occurring quinazolinone alkaloids. Tetrahedron 2006;62(42):9787-826
   Web of Science ®Google Scholar
• Cao SL, Feng YP, Jiang YY, Synthesis and in vitro antitumor activity of 4(3H)-quinazolinone derivatives with dithiocarbamate side chains. Bioorg Med Chem Lett 2005;15(7):1915-17
   PubMed Web of Science ®Google Scholar
• Suresha GP, Prakasha KC, Kapfo W, Synthesis and antimicrobial activity of quinazolinone conjugated peptides. Eur J Chem 2010;7(2):449-56
   Web of Science ®Google Scholar
• Gao XW, Cai XJ, Yan K, Synthesis and antiviral bioactivities of 2-Aryl- or 2-methyl-3-(substituted- benzalamino)-4(3H)-quinazolinone derivatives. Molecules 2007;12(12):2621-42
   PubMed Web of Science ®Google Scholar
• Wright WB, Tomcufcik AS, Chan PS, Antitumor actions of imidazolyl-(4-oxoquinazolin-3(4H)-yl)-acetamides against Ehrlich Ascites Carcinoma. J Med Chem 1987;30:2277-83
   PubMed Web of Science ®Google Scholar
• Yesilada A, Koyunoglu S, Saygilia N, Synthesis, anti-inflammatory and analgesic activity of some new 4(3H)-quinazolinone derivatives. Arch Pharm Pharm Med Chem 2004;337:96-104
   PubMed Web of Science ®Google Scholar
• Usifoh CO, Scriba GK. Synthesis and anticonvulsant activity of acetylenic quinazolinone derivatives. Arch Pharm (Weinheim) 2000;333(8):261-6
   PubMed Web of Science ®Google Scholar
• Zhu S, Wang J, Chandrashekar G, Synthesis and evaluation of 4-quinazolinone compounds as potential antimalarial agents. Eur J Med Chem 2010;45(9):3864-9
   PubMed Web of Science ®Google Scholar
• Trivedi PB, Undavia NK, Dave AM, Synthesis and antimicrobial activity of some heterocyclic compounds. Indian J Chem 1993;32B:497-500
   Google Scholar
• Alagarsamy V, Meena S, Revathi R. Anti HIV, antibacterial and antifungal activites of some 2,3-disubstituted quinazolin-4(3H)-ones. Indian J Pharm Sci 2004;4:459-462
   Google Scholar
• Mohamed MS, Kamel MM, Kassem EM, Novel 3-(p-substituted phenyl)-6-bromo-4(3H)-quinazolinone derivatives of promising antiinflammatory and analgesic properties. Acta Pol Pharm 2009;66(5):487-500
   PubMed Web of Science ®Google Scholar
• Terashima K, Shimamura H, Kawase A, Studies on antiulcer agents. IV. Antiulcer effects of 2-benzylthio5,6,7,8-tetrahydro-4(3H)-quinazolinones and related compounds. Chem Pharm Bull 1995;43(11):2021-3
   PubMed Web of Science ®Google Scholar
• Pandey A, Volkots DL, Seroogy JM, Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family. J Med Chem 2002;45(17):3772-93
   PubMed Web of Science ®Google Scholar
• Webb TR, Lvovskiy D, Kim S, Quinazolines as adenosine receptor antagonists: SAR and selectivity for A2B receptors. J Biorg Med Chem 2003;11(1):77-85
   PubMed Web of Science ®Google Scholar